A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

Hidradenitis Suppurativa (HS) Clinical Trial

Official title:

Lunsayil LTE: An Extension Trial Assessing Long-term Spesolimab Treatment in Patients With Hidradenitis Suppurativa (HS)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06241573
• Other study ID #: 1368-0130
• Secondary ID: 2023-508377-82-0
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: April 16, 2024
• Est. completion date: April 17, 2030

Study information

• Verified date: June 2024
• Source: Boehringer Ingelheim
• Contact: Boehringer Ingelheim
• Phone: 18002430127
• Email: clintriage.rdg[@]boehringer-ingelheim.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or study 1368-0100).

The purpose of this study is to find out how well people tolerate spesolimab and whether it helps people with HS in the long-term. For about 1.5 years, participants get spesolimab injections under the skin every 2 weeks.

Participants are in the study for about 2 years. During this time, participants have 41 visits. 24 visits are done at the study site. 17 visits can be done by video call at the participant's home. At study visits, doctors check the severity of the participant's HS and collect information on any health problems of the participants.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 550
• Est. completion date: April 17, 2030
• Est. primary completion date: April 17, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed and dated written informed consent in accordance with ICH Harmonized Guideline for Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.

2. Participants must be within the defined Residual Effect Period corresponding to 16 weeks since last spesolimab administration.

3. Participants who have completed treatment in the parent hidradenitis suppurativa (HS) spesolimab trial (1368-0098 (NCT05819398) or 1368-0100) without premature discontinuation and are willing and able to continue treatment in this trial.

4. Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.

Exclusion Criteria:

1. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.

2. Use of any drug considered by the investigator likely to interfere with the safe conduct of the trial since the last visit of the parent trials.

3. Use of immunomodulatory biologics or investigational agents since the last visit of the parent trials.

4. Participants who require / intend to use certain restricted medications such as immunomodulatory biologics or other investigational drugs/devices during the course of the trial.

5. Relevant chronic or acute infections including human immunodeficiency virus (HIV) and viral hepatitis. The corresponding laboratory tests will be performed at Visit 1. A participant can be re-screened if the participant was treated and is cured from the acute infection.

Further exclusion criteria apply.

Related Conditions & MeSH terms

• Hidradenitis
• Hidradenitis Suppurativa
• Hidradenitis Suppurativa (HS)

Intervention

Drug:
• Spesolimab
Spesolimab

Locations

Country	Name	City	State
Canada	SimcoDerm Medical and Surgical Dermatology Centre	Barrie	Ontario
Canada	Dr. S. K. Siddha Medicine Professional Corporation	Newmarket	Ontario
Singapore	National University Hospital	Singapore

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

Canada,  Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of treatment emergent adverse events (TEAE)		up to 92 weeks

External Links

•   Related Info